Immunocore Holdings PLC
NASDAQ:IMCR

Watchlist Manager
Immunocore Holdings PLC Logo
Immunocore Holdings PLC
NASDAQ:IMCR
Watchlist
Price: 36.64 USD -3.86% Market Closed
Market Cap: 1.9B USD

Immunocore Holdings PLC
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Immunocore Holdings PLC
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Immunocore Holdings PLC
NASDAQ:IMCR
Cash from Operating Activities
ÂŁ26.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Cash from Operating Activities
-$142.1m
CAGR 3-Years
-2%
CAGR 5-Years
-89%
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Cash from Operating Activities
-$239.7m
CAGR 3-Years
-54%
CAGR 5-Years
-108%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Cash from Operating Activities
ÂŁ67.2m
CAGR 3-Years
25%
CAGR 5-Years
2%
CAGR 10-Years
7%
Avacta Group PLC
LSE:AVCT
Cash from Operating Activities
-ÂŁ25.8m
CAGR 3-Years
-18%
CAGR 5-Years
-8%
CAGR 10-Years
-26%
Oxford BioMedica PLC
LSE:OXB
Cash from Operating Activities
-ÂŁ7.8m
CAGR 3-Years
28%
CAGR 5-Years
-6%
CAGR 10-Years
3%
No Stocks Found

Immunocore Holdings PLC
Glance View

Market Cap
1.9B USD
Industry
Biotechnology

Immunocore Holdings PLC stands as a pioneering force in the field of immunotherapy, leveraging its proprietary T-cell receptor (TCR) technology to transform the treatment landscape for various severe diseases. Rooted in cutting-edge science, the British biotech firm develops novel therapeutic agents targeting cancer, infectious diseases, and autoimmune conditions. Its leading platform technology, known as ImmTACs (Immune Mobilizing Monoclonal TCRs Against Cancer), ingeniously redirects T-cells—an integral component of the immune system—to recognize and obliterate cancerous cells in a highly targeted manner. By focusing on ultra-specific peptide-major histocompatibility complex (pMHC) targets, Immunocore meticulously designs its therapies to minimize off-target effects and maximize efficacy in tackling conditions that have eluded traditional treatment methods. Financially, Immunocore operates through a strategic blend of commercial and collaborative partnerships, alongside its independent pipeline advancements. It generates revenue by licensing its innovative technology to larger pharmaceutical entities that seek to add cutting-edge biologics to their portfolios. Additionally, milestone and royalty payments from collaborative research initiatives contribute significantly to its financial foundation. These partnerships not only bolster Immunocore's revenue streams but also accelerate its research and development efforts, enabling a faster path to market for its groundbreaking treatments. As a result, the company stands at the confluence of science and commerce, channeling its unique TCR technology to make meaningful strides in medical innovation and patient care.

IMCR Intrinsic Value
64.82 USD
Undervaluation 43%
Intrinsic Value
Price

See Also

What is Immunocore Holdings PLC's Cash from Operating Activities?
Cash from Operating Activities
26.1m GBP

Based on the financial report for Dec 31, 2024, Immunocore Holdings PLC's Cash from Operating Activities amounts to 26.1m GBP.

What is Immunocore Holdings PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 1Y
786%

Over the last year, the Cash from Operating Activities growth was 786%.

Back to Top